ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag books academia drug development policy collaboration

A building at the Stanford University campus at sunrise
Stanford to Launch New Climate Change School This Fall
Amanda Heidt | May 5, 2022 | 4 min read
The launch of the Stanford Doerr School of Sustainability—the first new school at the university in 70 years—comes thanks to a $1.1 billion gift from a venture capitalist and his wife.
Best Places to Work Academia, 2011
The Scientist | Jul 1, 2011 | 9 min read
Whether it’s attending a Scottish dance party or asking physics buffs to custom build your tools, researchers at this year’s top institutions are getting creative at work.
Minding the Drug Development Gap
Edward Spack | Nov 6, 2005 | 6 min read
Twenty-five years after the enactment of the Bayh-Dole Act, scientists and administrators in academia who are interested in moving bench discoveries to the clinic are learning what travelers in London's subway system already know: It's important to "mind the gap."
Tag, You're It
Carina Storrs | Feb 1, 2014 | 7 min read
A guide to DNA-encoded libraries for drug discovery
Pain Researcher Quits Academia, Takes Lab Home with Him
Jef Akst | May 1, 2021 | 6 min read
After resigning from the University of New England last year, Geoffrey Bove continues to study the effects of massage on rats in a facility he set up in his house.
The Scientist Staff | Mar 28, 2024
Illustration of scientists collaborating
How to Bring the Public into the Scientific Process
Amanda Heidt | Mar 14, 2022 | 10+ min read
A new wave of research is recruiting patients and other members of the public to serve as equal partners, bringing fresh perspectives to research on diseases and other conditions.
Opinion: Academia Suppresses Creativity
Fred Southwick | May 9, 2012 | 4 min read
By discouraging change, universities are stunting scientific innovation, leadership, and growth.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe

Run a Search

ADVERTISEMENT